Tumor localization with18F-2-fluoro-2-deoxy-D-glucose: Comparative autoradiography, glucose 6-phosphatase histochemistry, and histology of renally implanted sarcoma of the rat

Paul, Robert; Johansson, Risto; Kellokumpu‐Lehtinen, Pirkko; Söderström, Karl‐Ove; Kangas, Lauri

doi:10.1007/bf01854893

Cited by 32 publications

(10 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, the accumulation of (lSF)FDG into the renal tumors was apparently not the result of renal concentration of FDG, but rather of true metabolic trapping of the radiopharmaceutical into malignant tissue. This is, in fact, in accordance with a previous report of ours [9].…”

Section: Discussionsupporting

confidence: 95%

See 1 more Smart Citation

Dynamic (18F)-2-fluoro-2-deoxy-D-glucose (FDG) scintigraphy of normal and tumor-bearing rats

Paul

Parviainen

1986

Res. Exp. Med.

Self Cite

View full text Add to dashboard Cite

Five normal rats, 14 rats bearing the Rous sarcoma intrarenally, and four rats with DMBA-induced mammary carcinomas were imaged by dynamic (18F)-2-fluoro-2-deoxy-D-glucose ((18F)FDG) scintigraphy and (99mTc)DTPA renography. The brain, heart, liver, kidneys, and tumor were selected as regions of interest (ROI) for time activity curves; exponential functions were fitted to the decay-corrected curves, which yielded biologic half-lives of (18F)FDG in the ROI. It was found that all organs ROI's exhibited average elimination of activity, whereas activity accumulated in the tumor ROI for the duration of the study (5 h). The (99mTc)DTPA renographies showed that the excretory function in kidneys bearing the Rous sarcoma is severely impaired. This study shows that small laboratory animals can be successfully scintigraphied with a conventional gamma camera using (18F)FDG and that the pharmacokinetics of this radiopharmaceutical may be evaluated.

show abstract

Section: Discussionsupporting

confidence: 95%

“…The mammary tumors were induced by giving the rats 12 mg/ kg of DMBA six weeks before the study. The intrarenal tumor was prepared as described elsewhere [9].…”

Section: Experimental Animalsmentioning

confidence: 99%

Dynamic (18F)-2-fluoro-2-deoxy-D-glucose (FDG) scintigraphy of normal and tumor-bearing rats

Paul

Parviainen

1986

Res. Exp. Med.

Self Cite

View full text Add to dashboard Cite

show abstract

“…It has been proposed different hypothesis to explain this exacerbated glucose consumption, including the increase of hexokinase expression [49, 50], the decrease of glucose-6-phosphatase-mediated glucose dephosphorylation [51], and/or the overexpression of sugar transporters [52]. Agreed with this last explanation, GLUT1 overexpression has been observed in many human cancers.…”

Section: Expression Of Sugar Transporters In Cancermentioning

confidence: 99%

Potential Role of Sugar Transporters in Cancer and Their Relationship with Anticancer Therapy

Blanco-Calvo¹,

Figueroa²,

Pulido

et al. 2010

International Journal of Endocrinology

149

132

View full text Add to dashboard Cite

Sugars, primarily glucose and fructose, are the main energy source of cells. Because of their hydrophilic nature, cells use a number of transporter proteins to introduce sugars through their plasma membrane. Cancer cells are well known to display an enhanced sugar uptake and consumption. In fact, sugar transporters are deregulated in cancer cells so they incorporate higher amounts of sugar than normal cells. In this paper, we compile the most significant data available about biochemical and biological properties of sugar transporters in normal tissues and we review the available information about sugar carrier expression in different types of cancer. Moreover, we describe the possible pharmacological interactions between drugs currently used in anticancer therapy and the expression or function of facilitative sugar transporters. Finally, we also go into the insights about the future design of drugs targeted against sugar utilization in cancer cells.

show abstract

“…It has long been recognized that cancer cells have increased rates of glucose metabolism compared with healthy cells (15)(16)(17). A variety of mechanisms have been proposed for the accelerated glucose use seen in growing tumours and in transformed and malignant cells: increased concentrations of hexokinase (18,19), decreased rates of glucose-6-phosphatase mediated dephosphorylation (20) and enhanced rates of glucose uptake have been noted. Moreover, tumour cells can apparently express glucose transporters that are not substantially expressed in the non-malignant tissue.…”

Section: Introductionmentioning

confidence: 99%

Fructose transporter Glut5 expression in clear renal cell carcinoma

Villaamil

Gallego²,

Rubira³

et al. 2011

Oncol Rep

View full text Add to dashboard Cite

Abstract. Renal cell carcinomas (RCC) can be subclassified for general purposes into clear cell, papillary cell, chromophobe cell carcinomas and oncocytomas. Other tumours such as collecting duct, medullary, mucinous tubular and spindle cell and associated with Xp 11.2 translocations/TFE 3 gene fusion, are much less common. There is also a residual group of unclassified cases. Previous studies have shown that RCC has high glycolytic rates, and expresses GLUT transporters, but no distinction has been made among the different subtypes of renal cell tumours and their grades of malignancy. In clear renal cell carcinoma (cRCC) glycogen levels increase, glycolysis is activated and gluconeogenesis is reduced. The clear cell subtype of RCC is characterized histologically by a distinctive pale, glassy cytoplasm and this appearance of cRCC is due to abnormalities in carbohydrate and lipid metabolism, and this abnormality results in glycogen and sterol storage. Several isoforms of glucose carriers (GLUTs) have been identified. We show here in a panel of 80 cRCC samples a significant correlation between isoform 5 (GLUT5) and many pathological parameters such as grade of differentiation, pelvis invasion and breaking capsule. GLUT5 expression also appears to associate more strongly with the clear cell RCC subtype. These data suggest a role for the GLUT5 isoform in fructose uptake that takes place in cRCC cells and which subsequently leads to the malignant RCC progression.

show abstract

Tumor localization with18F-2-fluoro-2-deoxy-D-glucose: Comparative autoradiography, glucose 6-phosphatase histochemistry, and histology of renally implanted sarcoma of the rat

Cited by 32 publications

References 17 publications

Dynamic (18F)-2-fluoro-2-deoxy-D-glucose (FDG) scintigraphy of normal and tumor-bearing rats

Dynamic (18F)-2-fluoro-2-deoxy-D-glucose (FDG) scintigraphy of normal and tumor-bearing rats

Potential Role of Sugar Transporters in Cancer and Their Relationship with Anticancer Therapy

Fructose transporter Glut5 expression in clear renal cell carcinoma

Contact Info

Product

Resources

About